Opinion
Video
Author(s):
The panel discusses factors to consider when determining best treatment options for patients with recurrent or advanced endometrial cancer, including traditional clinical trial endpoints, cost, chance for cure versus disease control, and most importantly, patient preference.
Sifting Through Data in Lung Cancer and Leukemia: Drs Levy and Saint Fleur
Updated MANIFEST-2 Data With Pelabresib/Ruxolitinib Support Paradigm Shift in Myelofibrosis
Ponatinib Showcases Long-Term Efficacy, Safety in CP-CML With T315I Mutations
Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC
2 Commerce Drive
Cranbury, NJ 08512